Cancers

Research

Jump to: Review

18 pages, 2312 KiB

Open AccessArticle

Biomarkers in Liquid Biopsies for Prediction of Early Liver Metastases in Pancreatic Cancer

by Anne-Sophie Mehdorn, Timo Gemoll, Hauke Busch, Katharina Kern, Silje Beckinger, Tina Daunke, Christoph Kahlert, Faik G. Uzunoglu, Alexander Hendricks, Florian Buertin, Uwe A. Wittel, Yoshiaki Sunami, Christoph Röcken, Thomas Becker and Susanne Sebens

Cancers 2022, 14(19), 4605; https://doi.org/10.3390/cancers14194605 - 22 Sep 2022

Cited by 3 | Viewed by 2655

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive solid malignancies with poor survival rates. Only 20% of the patients are eligible for R0-surgical resection, presenting with early relapses, mainly in the liver. PDAC patients with hepatic metastases have a worse outcome [...] Read more.

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive solid malignancies with poor survival rates. Only 20% of the patients are eligible for R0-surgical resection, presenting with early relapses, mainly in the liver. PDAC patients with hepatic metastases have a worse outcome compared to patients with metastases at other sites. Early detection of hepatic spread bears the potential to improve patient outcomes. Thus, this study sought for serum-based perioperative biomarkers allowing discrimination of early (EHMS ≤ 12 months) and late hepatic metastatic spread (LHMS > 12 months). Serum samples from 83 resectable PDAC patients were divided into EHMS and LHMS and analyzed for levels of inflammatory mediators by LEGENDplex^TM, which was validated and extended by Olink^® analysis. CA19-9 serum levels served as control. Results were correlated with clinicopathological data. While serum CA19-9 levels were comparable, Olink^® analysis confirmed distinct differences between both groups. It revealed significantly elevated levels of factors involved in chemotaxis and migration of immune cells, immune activity, and cell growth in serum of LHMS-patients. Overall, Olink^® analysis identified a comprehensive biomarker panel in serum of PDAC patients that could provide the basis for predicting LHMS. However, further studies with larger cohorts are required for its clinical translation. Full article

(This article belongs to the Special Issue Liquid Biopsy in Gastrointestinal Cancer Disease—from Bench to Beside)

► Show Figures

Figure 1

32 pages, 6480 KiB

Open AccessArticle

Comparative Panel Sequencing of DNA Variants in cf-, ev- and tumorDNA for Pancreatic Ductal Adenocarcinoma Patients

by Mareike Waldenmaier, Lucas Schulte, Jonathan Schönfelder, Axel Fürstberger, Johann M. Kraus, Nora Daiss, Tanja Seibold, Mareen Morawe, Thomas J. Ettrich, Hans A. Kestler, Christoph Kahlert, Thomas Seufferlein and Tim Eiseler

Cancers 2022, 14(4), 1074; https://doi.org/10.3390/cancers14041074 - 21 Feb 2022

Cited by 2 | Viewed by 2588

Abstract

Pancreatic ductal adenocarcinomas (PDACs) are tumors with poor prognosis and limited treatment options. Personalized medicine aims at characterizing actionable DNA variants by next-generation sequencing, thereby improving treatment strategies and outcomes. Fine-needle tumor biopsies are currently the gold standard to acquire samples for DNA [...] Read more.

Pancreatic ductal adenocarcinomas (PDACs) are tumors with poor prognosis and limited treatment options. Personalized medicine aims at characterizing actionable DNA variants by next-generation sequencing, thereby improving treatment strategies and outcomes. Fine-needle tumor biopsies are currently the gold standard to acquire samples for DNA profiling. However, liquid biopsies have considerable advantages as they are minimally invasive and frequently obtainable and thus may help to monitor tumor evolution over time. However, which liquid analyte works best for this purpose is currently unclear. Our study aims to directly compare tumor-, circulating free (cf-) and extracellular vesicle-derived (ev)DNA by panel sequencing of matching patient material. We evaluated copy number variations (CNVs), single nucleotide variants (SNVs) and insertions and deletions (indels). Our data show that evDNA contains significantly larger DNA fragments up to 5.5 kb, in line with previous observations. Stringent bioinformatic processing revealed a significant advantage of evDNA with respect to cfDNA concerning detection performance for SNVs and a numerical increase for indels. A combination of ev- and cfDNA was clearly superior for SNV detection, as compared to either single analyte, thus potentially improving actionable variant prediction upon further optimization. Finally, calling of CNVs from liquid biopsies still remained challenging and uninformative. Full article

(This article belongs to the Special Issue Liquid Biopsy in Gastrointestinal Cancer Disease—from Bench to Beside)

► Show Figures

Figure 1

15 pages, 1237 KiB

Open AccessArticle

Detection of Marker Associated with CTC in Colorectal Cancer in Mononuclear Cells of Patients with Benign Inflammatory Intestinal Diseases

by Johanna Born, Alexander Hendricks, Charlotte Hauser, Jan-Hendrik Egberts, Thomas Becker, Christian Röder and Susanne Sebens

Cancers 2022, 14(1), 47; https://doi.org/10.3390/cancers14010047 - 23 Dec 2021

Cited by 6 | Viewed by 2727

Abstract

Colorectal carcinoma (CRC) belongs to the most common tumor entities in western countries. Circulating tumor cells (CTC) in blood of CRC patients are a powerful prognostic and predictive biomarker. However, whether CTC-associated markers can also be used for early CRC detection and discrimination [...] Read more.

Colorectal carcinoma (CRC) belongs to the most common tumor entities in western countries. Circulating tumor cells (CTC) in blood of CRC patients are a powerful prognostic and predictive biomarker. However, whether CTC-associated markers can also be used for early CRC detection and discrimination from benign diseases is not known. This study investigated the presence of CTC-associated markers CK20, PLS3, LAD1, and DEFA5 in blood of patients with benign inflammatory intestinal disease (IID) and their correlation with malignancy. The detection rate of CK20 and DEFA5 significantly differed between diseased patients and healthy controls. LAD1 and PLS3 were detected in all samples with clear differences in gene expression. DEFA5 expression was higher in CRC and IID patients compared to healthy donors, while CK20 and PLS3 were lower in CRC compared to IID patients or healthy controls. Overall, all CTC-associated markers were detectable in blood of IID patients, but not correlating with inflammation severity. Finally, PLS3 emerged as a suitable marker for differentiation between malignant and non-malignant intestinal diseases or healthy controls, however its suitability for early CRC detection needs to be further validated. Full article

(This article belongs to the Special Issue Liquid Biopsy in Gastrointestinal Cancer Disease—from Bench to Beside)

► Show Figures

Figure 1

13 pages, 1583 KiB

Open AccessArticle

Detection of VAR2CSA-Captured Colorectal Cancer Cells from Blood Samples by Real-Time Reverse Transcription PCR

by Sara R. Bang-Christensen, Viatcheslav Katerov, Amalie M. Jørgensen, Tobias Gustavsson, Swati Choudhary, Thor G. Theander, Ali Salanti, Hatim T. Allawi and Mette Ø. Agerbæk

Cancers 2021, 13(23), 5881; https://doi.org/10.3390/cancers13235881 - 23 Nov 2021

Cited by 3 | Viewed by 2493

Abstract

Analysis of circulating tumor cells (CTCs) from blood samples provides a non-invasive approach for early cancer detection. However, the rarity of CTCs makes it challenging to establish assays with the required sensitivity and specificity. We combine a highly sensitive CTC capture assay exploiting [...] Read more.

Analysis of circulating tumor cells (CTCs) from blood samples provides a non-invasive approach for early cancer detection. However, the rarity of CTCs makes it challenging to establish assays with the required sensitivity and specificity. We combine a highly sensitive CTC capture assay exploiting the cancer cell binding recombinant malaria VAR2CSA protein (rVAR2) with the detection of colon-related mRNA transcripts (USH1C and CKMT1A). Cancer cell transcripts are detected by RT-qPCR using proprietary Target Enrichment Long-probe Quantitative Amplified Signal (TELQAS) technology. We validate each step of the workflow using colorectal cancer (CRC) cell lines spiked into blood and compare this with antibody-based cell detection. USH1C and CKMT1A are expressed in healthy colon tissue and CRC cell lines, while only low-level expression can be detected in healthy white blood cells (WBCs). The qPCR reaction shows a near-perfect amplification efficiency for all primer targets with minimal interference of WBC cDNA. Spike-in of 10 cancer cells in 3 mL blood can be detected and statistically separated from control blood using the RT-qPCR assay after rVAR2 capture (p < 0.01 for both primer targets, Mann-Whitney test). Our results provide a validated workflow for highly sensitive detection of magnetically enriched cancer cells. Full article

(This article belongs to the Special Issue Liquid Biopsy in Gastrointestinal Cancer Disease—from Bench to Beside)

► Show Figures

Figure 1

17 pages, 2864 KiB

Open AccessArticle

Circulating Tumor Cell Clusters Are Cloaked with Platelets and Correlate with Poor Prognosis in Unresectable Pancreatic Cancer

by Minji Lim, Suhyun Park, Hyoung-Oh Jeong, Sung Hee Park, Sumit Kumar, Aelee Jang, Semin Lee, Dong Uk Kim and Yoon-Kyoung Cho

Cancers 2021, 13(21), 5272; https://doi.org/10.3390/cancers13215272 - 20 Oct 2021

Cited by 25 | Viewed by 3788

Abstract

Circulating tumor cells (CTCs) are known to be heterogeneous and clustered with tumor-associated cells, such as macrophages, neutrophils, fibroblasts, and platelets. However, their molecular profile and clinical significance remain largely unknown. Thus, we aimed to perform a comprehensive gene expression analysis of single [...] Read more.

Circulating tumor cells (CTCs) are known to be heterogeneous and clustered with tumor-associated cells, such as macrophages, neutrophils, fibroblasts, and platelets. However, their molecular profile and clinical significance remain largely unknown. Thus, we aimed to perform a comprehensive gene expression analysis of single CTCs and CTC clusters in patients with pancreatic cancer and to identify their potential clinical relevance to provide personalized medicine. Epitope-independent, rapid (>3 mL of whole blood/min) isolation of single CTCs and CTC clusters was achieved from a prospective cohort of 16 patients with unresectable pancreatic cancer using a centrifugal microfluidic device. Forty-eight mRNA expressions of individual CTCs and CTC clusters were analyzed to identify pancreatic CTC phenotype. CTC clusters had a larger proportion of mesenchymal expression than single CTCs (p = 0.0004). The presence of CTC clusters positively correlated with poor prognosis (progression-free survival, p = 0.0159; overall survival, p = 0.0186). Furthermore, we found that most CTCs in these patients (90.7%) were cloaked with platelets and found the presence of a positive correlation between the increase in CTC clusters and rapid disease progression during follow-ups. Efficient CTC cluster isolation and analysis techniques will enhance the understanding of complex tumor metastasis processes and can facilitate personalized disease management. Full article

(This article belongs to the Special Issue Liquid Biopsy in Gastrointestinal Cancer Disease—from Bench to Beside)

► Show Figures

Figure 1

9 pages, 831 KiB

Open AccessArticle

Identification and Comprehensive Co-Detection of Necrotic and Viable Aneuploid Cancer Cells in Peripheral Blood

by Alexander Y. Lin, Daisy Dandan Wang, Linda Li and Peter Ping Lin

Cancers 2021, 13(20), 5108; https://doi.org/10.3390/cancers13205108 - 12 Oct 2021

Cited by 7 | Viewed by 2093

Abstract

Aneuploid circulating tumor cells (CTCs, CD31⁻) and circulating tumor endothelial cells (CTECs, CD31⁺) exhibit an active interplay in peripheral blood, and play an essential role in tumorigenesis, neoangiogenesis, disease progression, therapy-resistant minimal residual disease (MRD), cancer metastasis and relapse. [...] Read more.

Aneuploid circulating tumor cells (CTCs, CD31⁻) and circulating tumor endothelial cells (CTECs, CD31⁺) exhibit an active interplay in peripheral blood, and play an essential role in tumorigenesis, neoangiogenesis, disease progression, therapy-resistant minimal residual disease (MRD), cancer metastasis and relapse. Currently, most CTC detection techniques are restricted to the indistinguishable quantification of circulating rare cells, including both necrotic and viable cells in cancer patients. Clinically imperative demands to distinguish and detect live and/or dead non-hematological aneuploid cancer cells in peripheral blood, which will assist in the rapid evaluation of therapeutic effects, real-time monitoring of treatment resistance longitudinally developed along with therapy and the effective detection of post-therapeutic MRD, have not yet been achieved. The integrated subtraction enrichment and immunostaining-fluorescence in situ hybridization (SE-iFISH)-derived novel strategy was developed in this study, aiming to precisely identify and detect live and necrotic cancer cells (NC) enriched from carcinoma patients’ biofluids. The innovative SE-iFISH (NC) provides a meaningful and practical approach to co-detect various viable and necrotic aneuploid CTCs and CTECs. The detected circulating rare cells can be characterized and categorized into diverse subtypes based upon cell viability, morphology, multiple tumor markers’ expression, and the degree of aneuploidy relevant to both malignancy and therapeutic resistance. Each subtype of live or necrotic CTCs and CTECs possesses distinct utility in anti-cancer drug development, translational research, and clinical practice. Full article

(This article belongs to the Special Issue Liquid Biopsy in Gastrointestinal Cancer Disease—from Bench to Beside)

► Show Figures

Graphical abstract

Review

Jump to: Research

39 pages, 1336 KiB

Open AccessReview

Current Applications of Liquid Biopsy in Gastrointestinal Cancer Disease—From Early Cancer Detection to Individualized Cancer Treatment

by Paul David, Anke Mittelstädt, Dina Kouhestani, Anna Anthuber, Christoph Kahlert, Kai Sohn and Georg F. Weber

Cancers 2023, 15(7), 1924; https://doi.org/10.3390/cancers15071924 - 23 Mar 2023

Cited by 4 | Viewed by 3746

Abstract

Worldwide, gastrointestinal (GI) cancers account for a significant amount of cancer-related mortality. Tests that allow an early diagnosis could lead to an improvement in patient survival. Liquid biopsies (LBs) due to their non-invasive nature as well as low risk are the current focus [...] Read more.

Worldwide, gastrointestinal (GI) cancers account for a significant amount of cancer-related mortality. Tests that allow an early diagnosis could lead to an improvement in patient survival. Liquid biopsies (LBs) due to their non-invasive nature as well as low risk are the current focus of cancer research and could be a promising tool for early cancer detection. LB involves the sampling of any biological fluid (e.g., blood, urine, saliva) to enrich and analyze the tumor’s biological material. LBs can detect tumor-associated components such as circulating tumor DNA (ctDNA), extracellular vesicles (EVs), and circulating tumor cells (CTCs). These components can reflect the status of the disease and can facilitate clinical decisions. LBs offer a unique and new way to assess cancers at all stages of treatment, from cancer screenings to prognosis to management of multidisciplinary therapies. In this review, we will provide insights into the current status of the various types of LBs enabling early detection and monitoring of GI cancers and their use in in vitro diagnostics. Full article

(This article belongs to the Special Issue Liquid Biopsy in Gastrointestinal Cancer Disease—from Bench to Beside)

► Show Figures

Figure 1

17 pages, 978 KiB

Open AccessReview

Circulating Nucleic Acids as Novel Biomarkers for Pancreatic Ductal Adenocarcinoma

by Ryan McGowan, Áine Sally, Anthony McCabe, Brian Michael Moran and Karen Finn

Cancers 2022, 14(8), 2027; https://doi.org/10.3390/cancers14082027 - 17 Apr 2022

Cited by 4 | Viewed by 2621

Abstract

Despite considerable advancements in the clinical management of PDAC it remains a significant cause of mortality. PDAC is often diagnosed at advanced stages due to vague symptoms associated with early-stage disease and a lack of reliable diagnostic biomarkers. Late diagnosis results in a [...] Read more.

Despite considerable advancements in the clinical management of PDAC it remains a significant cause of mortality. PDAC is often diagnosed at advanced stages due to vague symptoms associated with early-stage disease and a lack of reliable diagnostic biomarkers. Late diagnosis results in a high proportion of cases being ineligible for surgical resection, the only potentially curative therapy for PDAC. Furthermore, a lack of prognostic biomarkers impedes clinician’s ability to properly assess the efficacy of therapeutic interventions. Advances in our ability to detect circulating nucleic acids allows for the advent of novel biomarkers for PDAC. Tumor derived circulating and exosomal nucleic acids allow for the detection of PDAC-specific mutations through a non-invasive blood sample. Such biomarkers could expand upon the currently limited repertoire of tests available. This review outlines recent developments in the use of molecular techniques for the detection of these nucleic acids and their potential roles, alongside current techniques, in the diagnosis, prognosis and therapeutic governance of PDAC. Full article

(This article belongs to the Special Issue Liquid Biopsy in Gastrointestinal Cancer Disease—from Bench to Beside)

► Show Figures

Figure 1

Journal Menu

Journal Browser

Liquid Biopsy in Gastrointestinal Cancer Disease—from Bench to Beside

Share This Special Issue

Special Issue Editors

Special Issue Information

Keywords

Benefits of Publishing in a Special Issue

Published Papers (8 papers)

Research

Review

Further Information

Guidelines

MDPI Initiatives

Follow MDPI